Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle‐Invasive Urothelial Carcinoma
International Journal of Urology · 2026
DOI: 10.1111/iju.70664 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Urology, 2026. Verfasst von Satoshi Katayama und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. Hauptthemen laut MEDLINE: Nivolumab, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Ureteral Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Perioperative immunotherapy has become the standard of care in patients with high‐risk muscle‐invasive urothelial carcinoma (MIUC). This study aimed to clarify oncological outcomes and safety profiles of adjuvant nivolumab therapy in MIUC, focusing on upper tract urothelial carcinoma (UTUC).
Methods
This multicenter study comprised 97 patients undergoing removal of primary tumors, followed by adjuvant nivolumab therapy with a potential follow‐up period ≥ 12 months. Patients were divided according to the primary tumor location: bladder cancer (BC), n = 66 (68%); UTUC, n = 31 (32%). Multivariable Cox regression analyses were applied to identify prognostic factors for disease‐free survival (DFS).
Results
Before surgery, 38% of patients had an estimated glomerular filtration rate (eGFR) < 50 mL/min/1.73m 2 , but this proportion increased to 57% at nivolumab initiation with 19% of UTUC having eGFR < 30. The overall DFS at 6 months was 61.5%. DFS did not differ significantly between BC and UTUC ( p = 0.83). On multivariable analyses, a higher absolute eosinophil count was significantly associated with worse DFS (HR 2.24; 95% CI, 1.24–4.03, p = 0.007), while primary tumor location was not. Immune‐related adverse events (irAEs) of adrenal insufficiency and hypophysitis occurred in 8% and 4% of patients, respectively, with grade ≥ 3 occurring at 3.3–18.3 months.
Conclusions
Adjuvant nivolumab therapy may provide comparable oncological outcomes between BC and UTUC. Baseline eosinophil count was an independent prognosticator for DFS. The incidences of adrenal insufficiency and hypophysitis appeared higher in our real‐world data. Clinicians should recognize these irAEs due to nonspecific symptoms and considerable variability in time of onset.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
- Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
- Department of Urology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
- Department of Urology, National Hospital Organization Iwakuni Clinical Center, Yamaguchi, Japan.
- Department of Urology, Shimane University Hospital, Shimane, Japan.
ORCID-Profile: Satoshi Katayama, Tatsushi Kawada, Keiichiro Mori, Shota Inoue, Tomofumi Watanabe, Ichiro Tsuboi, Tomoaki Yamanoi, Takehiro Iwata, Kazuma Tsuboi, Kohei Ogawa, Akihiro Matsukawa, Takafumi Yanagisawa, Shingo Nishimura, Kensuke Bekku, Koichiro Wada, Takahiro Kimura, Motoo Araki
Zitieren
APA
Katayama, S., Kawada, T., Mori, K., Iwatani, K., Inoue, S., Watanabe, T., Tsuboi, I., Yamanoi, T., Iwata, T., Tsuboi, K., Murao, W., Nakada, T., Ogawa, K., Matsukawa, A., Yanagisawa, T., Nishimura, S., Bekku, K., Wada, K., Kimura, T., & Araki, M. (2026). Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle‐Invasive Urothelial Carcinoma. International Journal of Urology. https://doi.org/10.1111/iju.70664
Vancouver
Katayama S, Kawada T, Mori K, Iwatani K, Inoue S, Watanabe T, et al. Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle‐Invasive Urothelial Carcinoma. International Journal of Urology. 2026. doi:10.1111/iju.70664
BibTeX
@article{Katayama2026,
author = {Katayama, Satoshi and Kawada, Tatsushi and Mori, Keiichiro and Iwatani, Kosuke and Inoue, Shota and Watanabe, Tomofumi and Tsuboi, Ichiro and Yamanoi, Tomoaki and Iwata, Takehiro and Tsuboi, Kazuma and Murao, Wataru and Nakada, Tetsuya and Ogawa, Kohei and Matsukawa, Akihiro and Yanagisawa, Takafumi and Nishimura, Shingo and Bekku, Kensuke and Wada, Koichiro and Kimura, Takahiro and Araki, Motoo},
title = {Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle‐Invasive Urothelial Carcinoma},
journal = {International Journal of Urology},
year = {2026},
doi = {10.1111/iju.70664}
}
EUVIMED